FGFR1 and ovarian carcinoma: Although our studies are supported by findings in other cancers where FGFR1 upregulation has been observed after BET inhibition, such as uveal melanoma, breast cancer, or ovarian cancer cells52,53, we are the first to demonstrate that this is an early event in the intrinsic resistance mechanism.